Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study
Por:
Armario-Hita, JC, Pereyra-Rodriguez, JJ, González-Quesada, A, Herranz, P, Suarez, R, Galan-Gutiérrez, M, Rodríguez-Serna, M, de Frutos, JO, Carrascosa, JM, Serra-Baldrich, E, Ara-Martin, M, Figueras-Nart, I, Silvestre, JF, Zaragoza-Ninet, V, Ruiz-Villaverde, R
Publicada:
21 jun 2024
Ahead of Print:
1 jun 2024
Resumen:
BackgroundAbrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real-world data on its efficacy and safety in treating moderate-to-severe atopic dermatitis (AD) remains limited.ObjectivesThis study aimed to evaluate the short-term effectiveness and safety of abrocitinib in a real-life setting for patients with moderate-to-severe AD.MethodsWe conducted a retrospective multicenter study involving adult patients with moderate-to-severe AD who started abrocitinib treatment between May 1, 2023, and September 30, 2023, in 15 Spanish hospitals. Treatment doses were 100 or 200 mg daily, based on clinical assessment. Data collection included patient demographics, AD history, comorbidities, previous treatments, and disease severity indicators such as SCORing atopic dermatitis (SCORAD), Eczema Area and Severity Index (EASI), body surface area, and Peak Pruritus NRS scores at baseline, 4, 12, and 24 weeks. Quality of life was measured using the Dermatology Life Quality Index (DLQI), and safety was assessed by monitoring adverse reactions and various biochemical parameters.ResultsThe cohort comprised 76 patients with an average age of 33.93 years; 57.89% were male. Before abrocitinib, 36.84% were na & iuml;ve to advanced therapies. The baseline mean scores were SCORAD 47.04, EASI 21.79, and DLQI 15.01. At Week 24, there were significant improvements: EASI was reduced to 2.81, and 70.58% of the patients achieved EASI 75. However, 18.42% discontinued treatment mainly due to inefficacy or adverse effects. The safety profile was favorable, with 22.37% reporting mild adverse events (AEs) and one serious case of cutaneous lymphoma.ConclusionsThis first Spanish series assessing abrocitinib in real-world conditions reveals a significant improvement in AD symptoms and quality of life in a range of severity and prior treatment failures. Abrocitinib was well-tolerated, with few serious AEs, highlighting its potential as an effective treatment option for AD.
Filiaciones:
Armario-Hita, JC:
Univ Cadiz, Univ Hosp Puerto Real, Dept Dermatol, Cadiz, Spain
Pereyra-Rodriguez, JJ:
Univ Hosp Virgen Rocio, Dept Dermatol, Avda Manuel Siurot S-N, Seville 41013, Spain
Univ Seville, Sch Med, Dept Med, Seville, Spain
González-Quesada, A:
Univ Hosp Dr Negrin, Dept Dermatol, Gran Canarias, Spain
Herranz, P:
Univ Hosp La Paz, Dept Dermatol, Madrid, Spain
Suarez, R:
Univ Hosp Gregorio Maranon, Dept Dermatol, Madrid, Spain
Galan-Gutiérrez, M:
Univ Hosp Reina Sofia, Dept Dermatol, Cordoba, Spain
Rodríguez-Serna, M:
Univ Hosp Fe, Dept Dermatol, Valencia, Spain
de Frutos, JO:
Univ Hosp 12 Octubre, Dept Dermatol, Madrid, Spain
Carrascosa, JM:
Univ Hosp Germans Trias i Pujol, Dept Dermatol, Badalona, Spain
Serra-Baldrich, E:
Univ Hosp San Pau, Dept Dermatol, Hosp Sant Pau, Barcelona, Spain
Ara-Martin, M:
Univ Hosp Lozano Blesa, Dept Dermatol, Zaragoza, Spain
Figueras-Nart, I:
Univ Hosp Bellvitge, Dept Dermatol, Barcelona, Spain
Silvestre, JF:
Univ Gen Hosp Alicante, Dept Dermatol, Alicante, Spain
Zaragoza-Ninet, V:
Univ Hosp Valencia, Dept Dermatol, Valencia, Spain
Ruiz-Villaverde, R:
Univ Hosp San Cecilio, Dept Dermatol, Granada, Spain
hybrid
|